Key facts
- This page summarizes Jon Snodgres's Form 4 filing for REPLIGEN CORP (RGEN).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Mar 2023, 16:33.
Jon Snodgres - 02 Mar 2023 Form 4 Insider Report for REPLIGEN CORP (RGEN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RGEN
- Reported as of
- 02 Mar 2023
- Net transaction value
- -$690,712
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 16:33:56 UTC
- Prior SEC filing
- 01 Mar 2023
- Next SEC filing
- 16 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kimberly Brown (Attorney in Fact)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jon Snodgres filed Form 4 for REPLIGEN CORP (RGEN) on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 01 Mar 2023.
- Current net transaction value: -$690,712.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGEN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,848
- Change %
- +17%
- Price
- $0.000000
- Shares after
- 32,970
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
RGEN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,795
- Change %
- +27%
- Price
- $0.000000
- Shares after
- 41,765
- Date
- 03 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
RGEN
transaction
Common Stock
Tax liability
- Transaction value
- $690,712
- Shares
- -3,674
- Change %
- -8.8%
- Price
- $188.00
- Shares after
- 38,091
- Date
- 03 Mar 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RGEN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,019
- Change %
- Price
- $0.000000
- Shares after
- 5,019
- Date
- 02 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,019
- Exercise price
- $180.48
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Mr. Snodgres was awarded 4,848 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Footnote F2
Represents 625 shares issued pursuant to a Performance Stock Unit ("PSU") award granted to the Issuer on January 1, 2022, and 8,170 shares issued pursuant to a PSU award granted to the Issuer on February 27, 2020. The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria set forth in the PSU awards.
Footnote F3
Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the settlement of the PSUs.
Footnote F4
One third of the stock options will vest and become exercisable annually on March 2, 2024, March 2, 2025, and March 2, 2026.